TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of a Cognitive Intervention for Older Adults
Brief Summary: The purpose of the ACTIVE study was to test if cognitive training interventions could maintain functional independence in elders by improving basic mental abilities, with follow-up assessments through five years.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: complex cognitive training | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: complex cognitive training | Intervention Type: BEHAVIORAL; Name: complex cognitive training; Assigned to Arm(s): 1, 2
B: Arm Label: Memory Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Training | Arm Label: Reasoning Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Training | Arm Label: Speed of Processing Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Training | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Training | Intervention Type: BEHAVIORAL; Name: Cognitive Training; Assigned to Arm(s): Control, Memory Training, Reasoning Training, Speed of Processing Training
C: Arm Label: ThinkingFit; Type: EXPERIMENTAL; Interventions: Procedure: ThinkingFit programme | Intervention Type: PROCEDURE; Name: ThinkingFit programme; Assigned to Arm(s): ThinkingFit
D: Arm Label: Standard health counseling at baseline; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Nutritional guidance, Behavioral: Exercise, Behavioral: Cognitive training, Other: Reduction of vascular risk factors | Intervention Type: BEHAVIORAL; Name: Nutritional guidance; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: Reduction of vascular risk factors; Assigned to Arm(s): Lifestyle counseling

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of a Cognitive Intervention for Older Adults
Brief Summary: The purpose of the ACTIVE study was to test if cognitive training interventions could maintain functional independence in elders by improving basic mental abilities, with follow-up assessments through five years.


Options:
A: Arm Label: Robot intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Robot assisted cognitive training | Arm Label: Conventional intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conventional cognitive training group | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Robot assisted cognitive training; Assigned to Arm(s): Robot intervention | Intervention Type: BEHAVIORAL; Name: Conventional cognitive training group; Assigned to Arm(s): Conventional intervention
B: Arm Label: Memory Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Training | Arm Label: Reasoning Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Training | Arm Label: Speed of Processing Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Training | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Training | Intervention Type: BEHAVIORAL; Name: Cognitive Training; Assigned to Arm(s): Control, Memory Training, Reasoning Training, Speed of Processing Training
C: Arm Label: Computerized Working Memory Training.; Type: SHAM_COMPARATOR; Interventions: Device: Computerized Working Memory Training. | Intervention Type: DEVICE; Name: Computerized Working Memory Training.; Assigned to Arm(s): Computerized Working Memory Training.
D: Arm Label: ThinkingFit; Type: EXPERIMENTAL; Interventions: Procedure: ThinkingFit programme | Intervention Type: PROCEDURE; Name: ThinkingFit programme; Assigned to Arm(s): ThinkingFit

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of a Cognitive Intervention for Older Adults
Brief Summary: The purpose of the ACTIVE study was to test if cognitive training interventions could maintain functional independence in elders by improving basic mental abilities, with follow-up assessments through five years.


Options:
A: Arm Label: Computerized Working Memory Training.; Type: SHAM_COMPARATOR; Interventions: Device: Computerized Working Memory Training. | Intervention Type: DEVICE; Name: Computerized Working Memory Training.; Assigned to Arm(s): Computerized Working Memory Training.
B: Arm Label: Nutritional Intervention; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutritional Intervention | Arm Label: Physical Exercise; Type: EXPERIMENTAL; Interventions: Other: Physical Exercise | Arm Label: Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Cognitive Training | Arm Label: Combined; Type: EXPERIMENTAL; Interventions: Other: Combined | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutritional Intervention; Assigned to Arm(s): Nutritional Intervention | Intervention Type: OTHER; Name: Physical Exercise; Assigned to Arm(s): Physical Exercise | Intervention Type: OTHER; Name: Cognitive Training; Assigned to Arm(s): Cognitive Training | Intervention Type: OTHER; Name: Combined; Assigned to Arm(s): Combined | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Control Group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: complex cognitive training | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: complex cognitive training | Intervention Type: BEHAVIORAL; Name: complex cognitive training; Assigned to Arm(s): 1, 2
D: Arm Label: Memory Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Training | Arm Label: Reasoning Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Training | Arm Label: Speed of Processing Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Training | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Training | Intervention Type: BEHAVIORAL; Name: Cognitive Training; Assigned to Arm(s): Control, Memory Training, Reasoning Training, Speed of Processing Training

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Infant Pain Responses Between Two Different Methods of Urine Collection for Diagnosis of Infection: Suprapubic Aspiration and Urinary Catheterization
Brief Summary: The purpose of this study is to determine which of the two procedures commonly used to collect urine, percutaneous suprapubic aspiration (SPA) and urethral catheterization (UC), is less painful, and the success rates and complication rates associated with both methods.


Options:
A: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: water; Type: EXPERIMENTAL; Interventions: Other: sterile water | Arm Label: sucrose; Type: EXPERIMENTAL; Interventions: Drug: Sucrose | Arm Label: pacifier; Type: EXPERIMENTAL; Interventions: Device: Pacifier | Arm Label: water and pacifier; Type: EXPERIMENTAL; Interventions: Device: Pacifier | Arm Label: sucrose and pacifier; Type: EXPERIMENTAL; Interventions: Drug: Sucrose, Device: Pacifier | Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): sucrose, sucrose and pacifier | Intervention Type: DEVICE; Name: Pacifier; Assigned to Arm(s): pacifier, sucrose and pacifier, water and pacifier | Intervention Type: OTHER; Name: sterile water; Assigned to Arm(s): water
B: Arm Label: A; Type: OTHER; Interventions: Other: aromatherapy massage | Arm Label: B; Type: OTHER; Interventions: Other: aromatherapy massage | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: aromatherapy massage; Assigned to Arm(s): A, B
C: Intervention Type: PROCEDURE; Name: Percutaneous Suprapubic Aspiration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Urethral Catheterization; Assigned to Arm(s): N/A
D: Arm Label: Noanalgesia; Type: SHAM_COMPARATOR; Interventions: Procedure: Water 2mL PO 2 minutes prior to intra-muscular injection | Arm Label: Skin-to-skin; Type: EXPERIMENTAL; Interventions: Procedure: skin-to-skin contact | Arm Label: Glucose; Type: EXPERIMENTAL; Interventions: Procedure: Glucose 25% 2 mL PO 2 minutes prior to injection | Arm Label: Skin&Glucose; Type: EXPERIMENTAL; Interventions: Procedure: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards. | Intervention Type: PROCEDURE; Name: Water 2mL PO 2 minutes prior to intra-muscular injection; Assigned to Arm(s): Noanalgesia | Intervention Type: PROCEDURE; Name: skin-to-skin contact; Assigned to Arm(s): Skin-to-skin | Intervention Type: PROCEDURE; Name: Glucose 25% 2 mL PO 2 minutes prior to injection; Assigned to Arm(s): Glucose | Intervention Type: PROCEDURE; Name: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.; Assigned to Arm(s): Skin&Glucose

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Infant Pain Responses Between Two Different Methods of Urine Collection for Diagnosis of Infection: Suprapubic Aspiration and Urinary Catheterization
Brief Summary: The purpose of this study is to determine which of the two procedures commonly used to collect urine, percutaneous suprapubic aspiration (SPA) and urethral catheterization (UC), is less painful, and the success rates and complication rates associated with both methods.


Options:
A: Arm Label: Oral glucose solution + maternal holding; Type: EXPERIMENTAL; Interventions: Other: Oral glucose solution + maternal holding | Arm Label: Breastfeeding; Type: EXPERIMENTAL; Interventions: Other: Breastfeeding | Arm Label: Oral glucose solution; Type: ACTIVE_COMPARATOR; Interventions: Other: Oral glucose solution | Arm Label: Oral expressed breastmilk; Type: ACTIVE_COMPARATOR; Interventions: Other: Oral expressed breastmilk | Intervention Type: OTHER; Name: Oral glucose solution + maternal holding; Assigned to Arm(s): Oral glucose solution + maternal holding | Intervention Type: OTHER; Name: Breastfeeding; Assigned to Arm(s): Breastfeeding | Intervention Type: OTHER; Name: Oral glucose solution; Assigned to Arm(s): Oral glucose solution | Intervention Type: OTHER; Name: Oral expressed breastmilk; Assigned to Arm(s): Oral expressed breastmilk
B: Intervention Type: PROCEDURE; Name: Percutaneous Suprapubic Aspiration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Urethral Catheterization; Assigned to Arm(s): N/A
C: Arm Label: Fast injection; Type: EXPERIMENTAL; Interventions: Other: Fast injection speed by immunizer | Arm Label: Slow injection; Type: ACTIVE_COMPARATOR; Interventions: Other: Slow injection speed by immunizer | Intervention Type: OTHER; Name: Fast injection speed by immunizer; Assigned to Arm(s): Fast injection | Intervention Type: OTHER; Name: Slow injection speed by immunizer; Assigned to Arm(s): Slow injection
D: Arm Label: control; Type: N/A; Interventions: N/A | Arm Label: sucrose; Type: N/A; Interventions: N/A | Arm Label: physical intervention; Type: N/A; Interventions: N/A | Arm Label: physical intervention and sucrose; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.
Brief Summary: The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).


Options:
A: Arm Label: GEn (XP13512/GSK1838262) 600 mg; Type: EXPERIMENTAL; Interventions: Drug: GEn (XP13512/GSK1838262) | Arm Label: GEn (XP13512/GSK1838262) 1200 mg; Type: EXPERIMENTAL; Interventions: Drug: GEn (XP13512/GSK1838262) | Arm Label: GEn (XP13512/GSK1838262) 1800 mg; Type: EXPERIMENTAL; Interventions: Drug: GEn (XP13512/GSK1838262) | Arm Label: GEn (XP13512/GSK1838262) 2400 mg; Type: EXPERIMENTAL; Interventions: Drug: GEn (XP13512/GSK1838262) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GEn (XP13512/GSK1838262); Assigned to Arm(s): GEn (XP13512/GSK1838262) 1200 mg, GEn (XP13512/GSK1838262) 1800 mg, GEn (XP13512/GSK1838262) 2400 mg, GEn (XP13512/GSK1838262) 600 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: XP13512 (GSK1838262); Type: EXPERIMENTAL; Interventions: Drug: XP13512 (GSK1838262) | Intervention Type: DRUG; Name: XP13512 (GSK1838262); Assigned to Arm(s): XP13512 (GSK1838262) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Dopamine Agonist Group; Type: EXPERIMENTAL; Interventions: Other: Dopamine Agonist and Exercise | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Dopamine Agonist and Exercise | Intervention Type: OTHER; Name: Dopamine Agonist and Exercise; Assigned to Arm(s): Dopamine Agonist Group, Placebo Group
D: Arm Label: XP13512 600MG; Type: EXPERIMENTAL; Interventions: Drug: XP13512 600MG | Arm Label: XP13512 1200MG; Type: EXPERIMENTAL; Interventions: Drug: XP13512 1200MG | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: PLACEBO | Intervention Type: DRUG; Name: XP13512 600MG; Assigned to Arm(s): XP13512 600MG | Intervention Type: DRUG; Name: XP13512 1200MG; Assigned to Arm(s): XP13512 1200MG | Intervention Type: DRUG; Name: PLACEBO; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Phase 3, Controlled, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate (MTX) Compared to MTX Alone, in Methotrexate-Naive Patients With Active Rheumatoid Arthritis
Brief Summary: This is a phase III, randomized, controlled, double-blind, parallel group, international study in approximately 750 patients with active Rheumatoid Arthritis (RA) who are naive to Methotrexate (MTX) therapy. Rheumatoid Factor (RF)-positive and RF-negative patients will be enrolled and will be allocated equally between 3 treatment arms.


Options:
A: Arm Label: Group 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Biological: Golimumab 50 mg | Arm Label: Group 2: Golimumab 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 50 mg | Arm Label: Group 3: Golimumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Group 1: Placebo, Group 2: Golimumab 50 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Group 3: Golimumab 100 mg
B: Arm Label: Rituximab (0.5 g x 2) + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: folate, Drug: methotrexate, Drug: methylprednisolone, Drug: rituximab | Arm Label: Rituximab (1.0 g x 2) + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: folate, Drug: methotrexate, Drug: methylprednisolone, Drug: rituximab | Arm Label: Placebo + Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: folate, Drug: methotrexate, Drug: methylprednisolone, Drug: placebo | Intervention Type: DRUG; Name: folate; Assigned to Arm(s): Placebo + Methotrexate, Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Placebo + Methotrexate, Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): Placebo + Methotrexate, Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo + Methotrexate | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate
C: Arm Label: Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab
D: Arm Label: CDP870 200mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of CDP870 | Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): CDP870 200mg | Intervention Type: DRUG; Name: Placebo of CDP870; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 4 Efficacy Study of Antimicrobials in the Treatment of Acute Otitis Media in Young Children
Brief Summary: This is a prospective, randomized, double-blind, placebo controlled one-center study carried out in primary care setting of the health center of City of Turku, Finland. The study patients will be allocated to one of the two parallel treatment groups (amoxicillin-clavulanate or placebo). The hypothesis is that the symptoms and signs of acute otitis media are resolved more effectively with antimicrobial treatment than with placebo. Furthermore, this study aims at finding out prognostic factors that could help to direct antimicrobial treatment for correct subgroups of young patients.


Options:
A: Arm Label: Amoxicillin-clavulanate; Type: EXPERIMENTAL; Interventions: Drug: amoxicillin-clavulanate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: amoxicillin-clavulanate; Assigned to Arm(s): Amoxicillin-clavulanate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Amoxicillin-clavulanate; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin-clavulanate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amoxicillin-clavulanate, Drug: Placebo | Intervention Type: DRUG; Name: Amoxicillin-clavulanate; Assigned to Arm(s): Amoxicillin-clavulanate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: BEHAVIORAL; Name: Prescription Fill Status; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: amoxicillin-clavulanate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: amoxicillin-clavulanate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 4 Efficacy Study of Antimicrobials in the Treatment of Acute Otitis Media in Young Children
Brief Summary: This is a prospective, randomized, double-blind, placebo controlled one-center study carried out in primary care setting of the health center of City of Turku, Finland. The study patients will be allocated to one of the two parallel treatment groups (amoxicillin-clavulanate or placebo). The hypothesis is that the symptoms and signs of acute otitis media are resolved more effectively with antimicrobial treatment than with placebo. Furthermore, this study aims at finding out prognostic factors that could help to direct antimicrobial treatment for correct subgroups of young patients.


Options:
A: Intervention Type: BEHAVIORAL; Name: Prescription Fill Status; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: amoxicillin-clavulanate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: amoxicillin-clavulanate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Amoxicillin-clavulanate; Type: EXPERIMENTAL; Interventions: Drug: amoxicillin-clavulanate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: amoxicillin-clavulanate; Assigned to Arm(s): Amoxicillin-clavulanate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Amoxicillin-clavulanate; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin-clavulanate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amoxicillin-clavulanate, Drug: Placebo | Intervention Type: DRUG; Name: Amoxicillin-clavulanate; Assigned to Arm(s): Amoxicillin-clavulanate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis and Previously Treated With Biologic Anti- TNFa Agent(s)
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in subjects who have active rheumatoid arthritis and have been treated previously with at least 1 dose of a biologic anti-TNFa agent (etanercept, adalimumab or infliximab).


Options:
A: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab (D2E7) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab (D2E7); Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | Arm Label: Infliximab + MTX (DB); Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab (INF) + MTX, DB | Arm Label: Placebo + MTX (DB); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (PLA) + MTX, DB | Arm Label: Placebo + MTX switched to abatacept + MTX (DB); Type: EXPERIMENTAL; Interventions: Drug: PLA + MTX switched to ABA+ MTX, DB | Arm Label: Abatacept (open-label); Type: EXPERIMENTAL; Interventions: Drug: ABA, open-label (OL) | Intervention Type: DRUG; Name: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB); Assigned to Arm(s): Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]) | Intervention Type: DRUG; Name: Infliximab (INF) + MTX, DB; Assigned to Arm(s): Infliximab + MTX (DB) | Intervention Type: DRUG; Name: Placebo (PLA) + MTX, DB; Assigned to Arm(s): Placebo + MTX (DB) | Intervention Type: DRUG; Name: PLA + MTX switched to ABA+ MTX, DB; Assigned to Arm(s): Placebo + MTX switched to abatacept + MTX (DB) | Intervention Type: DRUG; Name: ABA, open-label (OL); Assigned to Arm(s): Abatacept (open-label)
C: Arm Label: Group 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Biological: Golimumab 50 mg | Arm Label: Group 2: Golimumab 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 50 mg | Arm Label: Group 3: Golimumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Group 1: Placebo, Group 2: Golimumab 50 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Group 3: Golimumab 100 mg
D: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A

Answer: C